The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Abstract
PURPOSE: To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens. PATIENTS AND METHODS: Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2.5 mg (n = 174), letrozole 0.5 mg (n = 188), or MA 160 mg (n = 189) once daily in a double-blind, multicenter trial. Data were analyzed for tumor response and safety variables up to 33 months of follow-up evaluation and for survival up to 45 months. RESULTS: Letrozole 2.5 mg produced a significantly higher overall objective response rate (24%) compared with MA (16%; logistic regression, P = .04) or letrozole 0.5 mg (13%; P = .004). Duration of objective response was significantly longer for letrozole 2.5 mg compared with MA (Cox regression, P = .02). Letrozole 2.5 mg was significantly superior to MA and letrozole 0.5 mg in time to treatment failure (P = .04 and P = .002, respectively). For time to progression, letrozole 2.5 mg was superior to letrozole 0.5 mg (P = .02), but not to MA (P = .07). There was a significant dose effect in overall survival in favor of letrozole 2.5 mg (P = .03) compared with letrozole 0.5 mg. Letrozole was significantly better tolerated than MA with respect to serious adverse experiences, discontinuation due to poor tolerability, cardiovascular side effects, and weight gain. CONCLUSION: The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399
Dowsett, M., Jones, A. L., Johnston, S. R. D., Jacobs, S., Trunet, P. F., & Smith, I. E. (1995) · PubMed · Cited by 258
Self-citationJonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
Bhatnagar, A. S., Häusler, A., Schieweck, K., Lang, M., & Bowman, R. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90460-3 · Cited by 246
Buzdar, A. U., Jones, S. E., Vogel, C. L., Wolter, J., Plourde, P., Webster, A., & for the Arimidex Study Group (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<730::aid-cncr10>3.0.co;2-0 · Cited by 207
Evans, T. R. J., di Salle, E., Ornati, G., Lassus, M., Benedetti, M. S., Pianezzola, E., & Coombes, R. C. (1992) · PubMed · Cited by 161
The EORTC Core Quality-of-Life Questionnaire: Interim Results of an International Field Study *
Aaronson, N. K., Ahmedzai, S. H., Bullinger, M., Crabeels, D., Estapé, J., Filiberti, A., Flechtner, H., Frick, U., Hürny, C., Kaasa, S., et al. (2021) · CRC Press eBooks · doi:10.1201/9781003068648-14 · Cited by 157
(1993) · PubMed · Cited by 130
Buzdar, A. U., Smith, R. A., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M. T., Cooper, J., & for the Multi-Institutional Trialist Collaborative Study Group (1996) · Cancer · Cited by 118
Howell, A., Mackintosh, J., Jones, M., Redford, J., Wagstaff, J., & Sellwood, R. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90046-6 · Cited by 106
Cited by
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Self-citationBonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Aromatase Inhibitors in the Treatment of Breast Cancer
Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0015 · Cited by 484
Ellis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., Fan, M., & Jun, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3832 · Cited by 483
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Aromatase, aromatase inhibitors, and breast cancer
Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401
Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period
Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., Kabbaj, O., Spano, J. P., Marsiglia, H., Rouzier, R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.095 · Cited by 394
Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 365
Self-citationBoulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Semiglazov, V. F., Semiglazov, V. V., Dashyan, G. A., Ziltsova, E. K., Ivanov, V. G., Bozhok, A. A., Melnikova, O. A., Paltuev, R. M., Kletzel, A., & Berstein, L. M. (2007) · Cancer · doi:10.1002/cncr.22789 · Cited by 333
Aromatase inhibitors for breast cancer: lessons from the laboratory
Johnston, S. R. D., & Dowsett, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1211 · Cited by 326
Lønning, P. E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P. D., Mickiewicz, E., Celio, L., Pitt, P., Mita, M., Aaronson, N. K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2234 · Cited by 316
Robertson, J. F. R., Osborne, C. K., Howell, A., Jones, S. E., Mauriac, L., Ellis, M., Kleeberg, U. R., Come, S. E., Vergote, I., Gertler, S., et al. (2003) · Cancer · doi:10.1002/cncr.11468 · Cited by 315
Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 298
Buzdar, A. U., Robertson, J. F. R., Eiermann, W., & Nabholtz, J. (2002) · Cancer · doi:10.1002/cncr.10908 · Cited by 290
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
Mauri, D., Pavlidis, N., Polyzos, N. P., & Ioannidis, J. P. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj357 · Cited by 286
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 259
Self-citationAromatase inhibitors for treatment of advanced breast cancer in postmenopausal women
Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003370.pub3 · Cited by 252
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
Attar, E., & Bulun, S. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.064 · Cited by 184
Letrozole: A Review of its Use in Postmenopausal Women with Advanced Breast Cancer
Lamb, H. M., & Adkins, J. C. (1998) · Drugs · doi:10.2165/00003495-199856060-00020 · Cited by 109
“c Interval between start of therapy and earliest diagnosis of progressive disease, withdrawal from therapy for any reason, death from any cause,[42] withdrawal of consent or lost to follow-up.[41]”
InfluentialPfister, C. U., Martoni, A., Zamagni, C., Lelli, G., De Braud, F., Souppart, C., Duval, M., & Hornberger, U. (2001) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.273 · Cited by 101
Self-citationAhmadi, S., Seraj, M., Chiani, M., Hosseini, S., Bazzazan, S., Akbarzadeh, I., Saffar, S., & Mostafavi, E. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s384085 · Cited by 44
“5 mg/day dosage of letrozole was associated with poorer response rates in this study.(76) In another study which developed and evaluated the effect of letrozole-loaded hyaluronic acid/chitosan-coated poly(d,l-lactide-co-glycolide) nanoparticles on 24 female albino mice (20–25 g) it was found that 300 mg/kg of the letr…”
ResultDranitsaris, G., Leung, P., Mather, J., & Oza, A. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200008000-00012 · Cited by 38
“Hence, letrozole was the second such agent to receive approval after the publication of two large randomized trials comparing letrozole to MA in one study and to aminoglutethamide in the other.(7,8) What was particularly interesting in these trials was that the response rate with letrozole 2.”
BackgroundMethodResultInfluential(2011) · Cited by 12
Metadata
- Authors
- Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., Fornasiero, A., Hoffmann, W., Michel, J., Hatschek, T., Tjabbes, T., Chaudri, H. A., Hornberger, U., & Trunet, P. F.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-02
- Volume
- 16
- Issue
- 2
- Pages
- 453-461
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1934173384
- Cited by
- 638
- References
- 21
- FWCI
- 20.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.